Upload
spa718
View
97
Download
2
Embed Size (px)
DESCRIPTION
Oropharyngeal cancers Pradit Rushatamukayanunt, MD
Citation preview
Human Papillomavirus and Oropharyngeal Cancer
Pradit Rushatamukayanunt MD, PhDDivision of Head Neck and Breast Surgery
Department of SurgeryFaculty of Medicine Siriraj Hospital
Mahidol University
Head and Neck Cancer
• 6th most common cancer worldwide
• > 95% caused by Squamous cell Carcinoma
• HNSCC - oral cavity, oropharynx, larynx or hypopharynx
• Known risk factors including tobacco, alcohol and betel nut
Changing Trend of Tobacco Use
• Reduction in tobacco use in the USA
• In 1965: > 50% of male and 0.25% of female
• In 2006: < 25% of male and 20% of female
• Numbers of head and neck cancer patient should be decreased ?
Giovino GA et al., Am J Prev Med, 33: s318-s326, 2007
Changing Trend of Tobacco Use and Epidemiology of HNC
Giovino GA et al., Am J Prev Med, 33: s318-s326, 2007
Changing Epidemiology of Head and Neck Cancer
• ↑ Incidence of tongue and pharynx in the past two decades
• SEER Data (1973-2001) showed ↑ annual incidence of Oropharyngeal carcinomas 0.8%
Oropharyngeal subsites: Base of tongue ↑1.27% Tonsillar carcinoma ↑0.6%
Chaturvedi AK, J Clin Oncol 2008
Global Trend for Oropharyngeal and Oral carcinoma among men
Chaturvedi AK, J Clin Oncol 2013
Among men, OPSCCsignificantly increased inmany developed countries
e.g. United States, Canada United Kingdom, Japan, the Netherlands, Denmark, Australia, Slovakia, Brazil
Incidence Trend of HNSCC in Thailand
Chaturvedi et al, J Clin Oncol 2013
Male Female
Incidence Trend of Oropharyngeal and Oral cavity SCC in Men and Women in Thailand
HPV as a Risk Factor in Oropharyngeal carcinoma
• Odds ratio for Oropharyngeal CA in seropositive HPV16 was more than 14 (Mork J, NEJM 2001)
• HPV-associated oropharyngeal carcinoma in the USA = 60-70% (D’Souza et al NEJM 2007)
(Fakhry C J Nat Can Inst 2008) (Chaturvedi AK J Clin Oncol 2011)
• HPV-associated OPSCC in Central Europe and Central America = 10%
(Ribeiro KB , Int J Epidemiol 2011)
• HPV 38-56% in North America, North and West Europe, Australia and Japan
• HPV 13-17% in other parts of the world (de Martel C , Lancet Oncol 2012)
HPV and HNSCC in Thailand
Siriraj Hospital Experiences
• Two PCR-based studies
• Prevalence of HPV positive =
27.3%
(HPV11 = 50%, HPV16 = 33%,
HPV26 = 17 )
Relatively low HPV detection
• Small population
• Methods of detection
• Different types of HPV
• Lifestyle and behaviour
Professor Harald Zur Hausen
Prince Mahidol Award 2005
Nobel Prize 2008
The First one who demonstrated HPV-DNA
sequences in cervical cancer biopsies and
cervical cancer cell lines
HPV Structure
L2
L1E6 E7 E1
E2 E5
E4
Oncogenic
Viral Replication
Assembly and
Release
Capsid proteins
(Zur Hausen, Nat Rev Cancer 2002)
Carcinogenic Effect caused by Oncoprotein E7
(Syrjänen S, Head and Neck Pathology 2012)
Carcinogenic Effect caused by Oncoprotein E6
(Syrjänen S, Head and Neck Pathology 2012)
HPV Pathogenesis
(Syrjänen S, Head and Neck Pathology 2012)
Clinical Types of HPV Infection
High Risk Types: found preferentially in precancerous and cancerous specimensincluding HPV 16,18,31,33,34,35,39,45,51,52,56,58,59,66,68,70
Low Risk Types: detected in wart and non-malignant lesionincluding HPV 6,11,42,43,44
(Syrjänen S, Head and Neck Pathology 2012)
Risk of HPV Infection
Oro-genital contact>1 partner
Young age of 1st Sexual IntercourseHistory of genital wart
Less oro-genital contactPartner 1-2
1st Sexual Intercourse 20.9 yrLack of history STD
Feature HPV-negative HPV-positive
Age Above 60 years Middle-aged
Risk factors Tobacco +/- alcohol Sexual behaviour
Field cancerization yes Unknown
Predilection site None Oropharynx
T stage Higher T Stage Lower T Stage
Nodal status Lower Higher
TP53 mutations Frequent Infrequent
Different Clinical and Biological Features of HPV-negative and HPV-positive Cases
HPV Positive: p16↑, p53 wt
Biological Features of HPV-negative and HPV-positive
HPV Positive: p16↓, p53 wt
(Leemans CR et al, Nat Rev Cancer 2011)
p16 ↑, wt p53
p16 ↓, mutant p53
Pathological Diagnosis
Typical morphology
1. Arise from the tonsillar crypts
2. Unassociated with dysplasia of the surface epithelium
3. Exhibit lobular growth
4. Permeated by infiltrating lymphocytes
5. Lack significant keratinization
6. Demonstrate a prominent “basaloid” morphology
Westra WH, Head and Neck Pathology 2009
Detection of HumanPapillomaVirus
Presence of HPV DNA
Evidence of functioning Oncoprotein E7
DNA In-Situ Hibridization
PCR assay for viral copies
mRNA of E6, E7
p16 Immunohistochemistry
HPV Detection
• Polymerase chain reaction
• High sensitivity
• Prone to cross contaminate
• Unable to distinguish episomal vs integrated form
• Best fit for frozen specimen
• Prone to error when analyze in FFPE specimen
• More widely available but not for some pathological lab
HPV Detection
• In situ hybridization
• High specificity
• Localize HPV DNA within the tumor cell nuclei
• Discriminate between integrated and episomal infection
• Limited to a few specialist centers
(Syrjänen S, Head and Neck Pathology 2002)
Detection of Functional Oncoproteins
• p-16 Immunohistochemistry
(Rushatamukayanunt et al,APJCP 2014)
• Surrogate of functional downstream effect of Rb gene inactivation by E7 oncoprotein
• Sensitivity 100%
• Specificity 79%
• Applicable for FFPE specimens
Smeets Sj et al, Int J Cancer 2007
p-16 Immunohistochemistry
(Rushatamukayanunt et al, APJCP 2014)
HPV as a prognostic marker
Ang KK, Sem in Rad Oncol2012
Interaction between HPV and Tobacco Consumption
(Ang KK, NEJM 2010)
HPV-ISH vs p16 status and survival
(Ang KK, NEJM 2010)
Ang KK, Sem in Rad Oncol2012
Application of Knowledge
HPV-positive Oropharyngeal Carcinoma has better prognosis
Better Survival
Long-term morbidity associated with current treatment will be
longer lasting
De-escalating Treatment Regimens
De-escalating Treatment Intensity
• Potential to reduce
• Gastric tube dependence
• Osteoradionecrosis
• Dysphagia
• Xerostomia
• Dental decay
• Hypothyroidism
• Carotid stenosis
• De-escalating Strategies
• Cetuximab as alternative to Cisplatin when given concurrently with radiation
• Reduction of radiation dose when combines with chemotherapy as primary treatment
• Reduction of adjuvant chemotherapy or radiotherapy dose following primary surgery
Conclusion
• HPV-positive tumour is important prognostic marker in
Oropharyngeal carcinoma
• HPV detection should be considered in patient with
middle-aged group, low tumour stage with high nodal status
• p16-IHC is the most practical method to determine HPV status
• Positive-HPV status is prognostic factor of better survival
Future Trend
• Actual HPV prevalence in various geographic regions
• Suitable method of HPV detectionsingle or combined method
• Additional effects of EGFR status and TP53 mutation on therapeutic response